

Japan Tobacco Inc. Clinical development (as of July 31, 2006)

| Code | Stage | Indication | Mechanism | Characteristics | Rights |
|-------------------|---------------------------------|--------------------------|---------------------------------------|--|---|
| JTT-705 (oral) | Phase1(JPN) | Dyslipidemia | CETP inhibitor | Decreases LDL and increases HDL by inhibition of CETP -CETP:Cholesteryl Ester Transfer Protein, facilitates transfer of cholesteryl ester from HDL to LDL -HDL:High density lipoprotein, Good Cholesterol -LDL:Low density lipoprotein, Bad Cholesterol | A license agreement was signed with Roche (Switzerland) for development and commercialization of this compound worldwide except Japan and Korea. (October 2004) |
| JTT-130 (oral) | Phase2(JPN) Phase2(Overseas) | Hyperlipidemia | MTP inhibitor | Treatment of hyperlipidemia by reducing absorption of cholesterol and triglyceride via inhibition of MTP MTP:Microsomal Triglyceride Transfer Protein | |
| JTK-303 (oral) | Phase1(JPN) | Anti-HIV | Integrase inhibitor | Integrase inhibitor which works by blocking integrase, an enzyme that is involved in the replication of HIV (HIV:Human Immunodeficiency Virus) | A license agreement was signed with Gilead (US) for development and commercialization of this compound worldwide except Japan . (March 2005) |
| JTT-302 (oral) | Phase1(Overseas) | Dyslipidemia | CETP inhibitor | Decreases LDL and increases HDL by inhibition of CETP -CETP:Cholesteryl Ester Transfer Protein, facilitates transfer of cholesteryl ester from HDL to LDL -HDL:High density lipoprotein, Good Cholesterol -LDL:Low density lipoprotein, Bad Cholesterol | |
| JTT-305 (oral) | Phase1(JPN) Phase1(Overseas) | Osteoporosis | CaSR antagonist | Increases BMD and decreases new vertebral fractures by accelerating endogenous PTH secretion via antagonism of circulating Ca on CaSR in parathyroid cells -BMD: Bone Mineral Density -PTH: Parathyroid Hormone -CaSR: Calcium-Sensing Receptor | |
| JTT-551 (oral) | Phase1(JPN) | Type 2 diabetes mellitus | PTP1B inhibitor | Decreases blood glucose by enhancing insulin signal via inhibition of PTP1B. -PTP1B:Protein Tyrosine Phosphatase 1B This enzyme negatively regulates insulin signaling pathway. | |
| JTT-552 (oral) | Phase1(JPN) | Hyperuricemia | URAT1 (Urate Transporter 1) inhibitor | Decreases serum urate concentration by increasing urinary urate excretion via inhibition of URAT1. -URAT 1: Urate Transporter 1 | |

Changes from the previous announcement on April 28, 2006:

JTT-130 advanced from phase1 to phase2 overseas.

JTT-305 entered into clinical trial stage overseas.

JTT-552 entered into clinical trial stage in Japan.